Grifols (GIFLF) Net Income (2009 - 2025)
Grifols' (GIFLF) quarterly Net Income came in at $1.4 billion in Q4 2025, up 13.57% on a YoY basis from $1.3 billion in Q4 2024, and up 13.57% quarter-over-quarter from $1.3 billion in Q4 2024.
Analysis
Grifols (GIFLF) Net Income (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Net Income for 16 consecutive years, with $1.4 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Income rose 13.57% year-over-year to $1.4 billion; the trailing twelve-month figure through Dec 2025 stood at $2.8 billion (up 147.7% YoY), and the FY2025 full-year result was $824.8 million, up 14.34% from the prior year.
- Net Income climbed to $1.4 billion in Q4 2025 per GIFLF's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Net Income topped out at $1.4 billion in Q4 2025 and bottomed at -$214.9 million in Q4 2021.
- Historically, Net Income has averaged $690.2 million across 4 years, with a median of $763.9 million in 2024.
- The sharpest annual moves came in 2021 and 2022: Net Income retreated 8.37% in 2021, then soared 217.68% in 2022.
- Over 4 years, Net Income stood at -$214.9 million in 2021, then jumped by 217.68% to $252.9 million in 2022, then jumped by 404.04% to $1.3 billion in 2024, then climbed by 13.57% to $1.4 billion in 2025.
- According to Business Quant data, Net Income over the past three periods registered $1.4 billion, $1.3 billion, and $252.9 million for Q4 2025, Q4 2024, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 1.45 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.45 Bn |
| Dec 31, 2024 | 1.27 Bn |
| Dec 31, 2022 | 252.92 Mn |
| Dec 31, 2021 | -214.92 Mn |
| Dec 31, 2020 | -198.33 Mn |
| Mar 31, 2020 | 330.09 Mn |
| Dec 31, 2019 | 804.11 Mn |
| Mar 31, 2019 | 194.84 Mn |
| Dec 31, 2018 | 817.44 Mn |
| Jun 30, 2018 | 260.55 Mn |
| Mar 31, 2018 | 264.14 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Jun 30, 2017 | 255.10 Mn |
| Mar 31, 2017 | 247.88 Mn |
| Dec 31, 2016 | 78.21 Mn |
| Sep 30, 2016 | 227.94 Mn |
| Jun 30, 2016 | 214.39 Mn |
| Mar 31, 2016 | 311.60 Mn |
| Dec 31, 2015 | 271.10 Mn |
| Sep 30, 2015 | 227.51 Mn |